Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China National Pharmaceutical Foreign Trade To Build Investment Platform For Pharmaceutical Industry

This article was originally published in PharmAsia News

Executive Summary

China National Pharmaceutical Foreign Trade Corporation, the wholly owned subsidiary of China National Pharmaceutical Group, has mapped out its medium- and long-term strategy that seeks strategic partnerships to establish an investment platform for the pharmaceutical industry. This will dovetail with the parent group's aim of consolidation and globalization of its pharmaceutical trade, technology and business. The trade corporation has collaborated with Otsuka Group, Johnson & Johnson, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, AstraZeneca and Kanebo and set up more than 10 joint ventures such as China Otsuka, Xian-Janssen, Shanghai Squibb, Suzhou Capsugel and Sino-Swed Pharmaceutical. It reported revenue of RMB 2 billion last year, with import and export amounting to RMB $300 million. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts